Dyne Therapeutics, Inc.DYNNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank69
5Y CAGR-19.0%
Year-over-Year Change
Year-over-year SG&A expense growth
5Y CAGR
-19.0%/yr
Long-term compound
Percentile
P69
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 24.14% |
| Q3 2025 | 0.71% |
| Q2 2025 | 3.96% |
| Q1 2025 | 4.06% |
| Q4 2024 | 19.01% |
| Q3 2024 | 32.58% |
| Q2 2024 | -60.60% |
| Q1 2024 | 178.36% |
| Q4 2023 | 25.95% |
| Q3 2023 | -7.68% |
| Q2 2023 | -4.06% |
| Q1 2023 | 14.01% |
| Q4 2022 | -8.61% |
| Q3 2022 | 24.92% |
| Q2 2022 | -19.29% |
| Q1 2022 | -21.87% |
| Q4 2021 | 54.40% |
| Q3 2021 | -0.59% |
| Q2 2021 | -3.32% |
| Q1 2021 | 0.12% |
| Q4 2020 | 69.25% |
| Q3 2020 | 186.43% |
| Q2 2020 | -23.98% |
| Q1 2020 | 45.66% |
| Q4 2019 | 87.17% |
| Q3 2019 | 39.59% |
| Q2 2019 | 0.00% |
| Q1 2019 | 0.00% |
| Q4 2017 | 43.18% |
| Q3 2017 | 4.76% |
| Q2 2017 | 5.00% |
| Q1 2017 | -9.09% |
| Q4 2016 | 7.32% |
| Q3 2016 | 5.13% |
| Q2 2016 | 5.41% |
| Q1 2016 | 8.82% |
| Q4 2015 | 17.24% |
| Q3 2015 | -17.14% |
| Q2 2015 | 16.67% |
| Q1 2015 | 109.74% |